Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.25USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$3.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,594
52-wk High
$5.40
52-wk Low
$2.25

Select another date:

Tue, Apr 17 2018

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Compugen Announces Exclusive License Agreement With Medimmune

* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Compugen, AstraZeneca unit in cancer drug development deal

JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.

BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18

* COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR Source text for Eikon: Further company coverage:

Select another date: